Metformin is a biguanide medication originally developed to treat type 2 diabetes. It works by reducing glucose production in the liver and improving insulin sensitivity. Over the past two decades, researchers identified a compelling secondary benefit: Metformin activates AMPK, a key cellular energy sensor linked to slowing biological aging, reducing inflammation, and improving metabolic health — making it one of the most studied longevity compounds in medicine.
Research suggests Metformin may extend healthspan through several mechanisms: activating the AMPK pathway (which mimics caloric restriction), reducing chronic inflammation, improving mitochondrial function, and potentially lowering cancer risk. The landmark TAME trial (Targeting Aging with Metformin) is currently investigating its direct effects on aging. Observational studies have found diabetic patients on Metformin outliving healthy non-diabetic controls.
For longevity protocols, most providers start at 500 mg once daily with dinner, gradually increasing to 1,000–1,500 mg per day as tolerated. Your Coby Health physician will evaluate your individual health profile and prescribe the right dosage for you. Extended-release (ER) formulations are often preferred, as they significantly reduce GI side effects.
Metformin may be appropriate for adults interested in proactive longevity support, particularly those with metabolic risk factors, a family history of type 2 diabetes, or an interest in evidence-based longevity protocols. It may not be appropriate for individuals with kidney disease, liver conditions, or certain other health factors. Your Coby Health provider will review your complete medical history before prescribing.
The most common side effects are gastrointestinal — nausea, diarrhea, or stomach discomfort — which typically resolve within the first few weeks. Taking Metformin with food and starting at a low dose significantly reduces these effects. Extended-release formulations further minimize GI symptoms. Rare but serious risks include lactic acidosis, which is why Metformin is contraindicated in those with significant kidney or liver impairment.